Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | TSPO | P30536 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10541028 | 0.95 | MLYCD (0.49) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL10540452 | 0.87 | MLYCD (0.46) | ALDH1A1TSHRMLYCDMEN1KMT2A | |
| SCHEMBL8439016 | 0.86 | ALDH1A1 (0.47) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL28294373 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL29873818 | 0.84 | ALDH1A1 (0.46) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL5813341 | 0.84 | MLYCD (0.45) | ALDH1A1TSHRMLYCDMEN1KMT2A | |
| SCHEMBL6609664 | 0.83 | ADRA2C (0.51) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL6901524 | 0.83 | MLYCD (0.50) | ALDH1A1TSHRGLAMLYCDMEN1 | |
| SCHEMBL5807041 | 0.83 | SMN1; SMN2 (0.60) | ALDH1A1TSHRGLAMEN1KMT2A | |
| SCHEMBL11155479 | 0.83 | MMP2 (0.49) | ALDH1A1MLYCDMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | claimed |
| EP-1455734-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | Yu, Ruey J., Dr. (US) | 2004-09-15 | — | — | EP | claimed |
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | YU RUEY J (US) | 2003-06-12 | — | — | US | claimed |
| WO-2003045338-A1 | COMPOSITIONS COMPRISING PHENYL-GLYCINE DERIVATIVES | YU RUEY J (US) | 2003-06-05 | — | — | WO | claimed |
| US-7160902-B2 | Amide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160902-B2 | Amide derivatives and methods of their use | ADOLOR CORPORATION (US) | 2007-01-09 | — | — | US | disclosed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | disclosed |
| WO-2005049564-A1 | AMIDE DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050107355-A1 | Amide derivatives and methods of their use | CUBIST PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-6824786-B2 | TOPICAL APPLYING COSMETIC | YU RUEY J (US) | 2004-11-30 | — | — | US | disclosed |
| US-4439524-A | Stereoselective resolution of phenylglycine derivatives with enzyme resins | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-27 | — | — | US | disclosed |
| EP-0073993-A2 | Optically pure alpha-aminophenylacetic acid derivatives, process for their preparation and their use in the preparation of medicines | BAYER AG (DE) | 1983-03-16 | — | — | EP | disclosed |
| EP-0022492-B1 | STEREO SELECTIVE RESOLUTION OF PHENYLGLYCINE DERIVATIVES WITH ENZYMERESINS | BAYER AG (DE) | 1982-09-29 | — | — | EP | disclosed |
| US-4260684-A | Stereoselective resolution of phenylglycine derivatives and 4-hydroxyphenylglycine derivatives with enzyme resins | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
| EP-0022492-A1 | Stereo selective resolution of phenylglycine derivatives with enzymeresins | BAYER AG (DE) | 1981-01-21 | — | — | EP | disclosed |
| EP-0003786-B1 | STEREOSELECTIVE SEPARATION OF PHENYLGLYCINE DERIVATIVES AND 4-HYDROXYPHENYLGLYCINE DERIVATIVES WITH ENZYME-CONTAINING POLYMERS | BAYER AG (DE) | 1980-12-10 | — | — | EP | disclosed |
| EP-0003786-A1 | Stereoselective separation of phenylglycine derivatives and 4-hydroxyphenylglycine derivatives with enzyme-containing polymers | BAYER AG (DE) | 1979-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108496-A1 | Compositions comprising phenyl-glycine derivatives | GRHPR, ARL1, SUCLG1 | ALDH1A1 1110/4885TSHR 3740/4885GLA 61/4885 |
| US-20050107355-A1 | Amide derivatives and methods of their use | HRH2, SLC10A2, ALPI | ALDH1A1 614/4885TSHR 3662/4885GLA 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.